CLAIMS

1. A compound of formula (Ia), or a pharmaceutically acceptable salt thereof:



(Ia)

wherein R_1 is selected from the group consisting of H, C_{1-3}alkyl, C_{1-3}alkoxy, CF_3, and halo;

R_2, R_3 and R_4 are H;

R_5 is C_{1-3}alkyl;

R_6 is C_{3-5}alkyl or $-CH_2C_{3-4}$cycloalkyl;

R_7 is selected from the group consisting of:



, and



;

each R_8 is independently selected from the group consisting of halo, C_{1-6}alkyl, C_{1-6}alkoxy, C_{3-6}cycloalkyl, CN, OH, C(O)OH, $C(O)OC_{1-3}$alkyl and CH_2OH;

R_9 is the group $-(CHR_{10})_s-(X)_t-(CHR_{10})_u-R_{11}$;

each R_{10} is independently selected from H, CH_3, OH and CH_2OH;

X is CH_2, NH or O;

R_{11} is a heterocycloalkyl or C_{3-6} cycloalkyl group which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of CH_3, OMe, OH, CH_2OH and halo;

r is 0, 1 or 2;

s is 0, 1 or 2;

t is 0 or 1;

u is 0, 1 or 2;

with the proviso that no more than two R_{10} groups represent CH_3, OH or CH_2OH.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 is H.

3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 and R_5 are each independently CH_3 or halo.

4. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 and R_5 are CH_3.
5. A compound according to any of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R_6 is selected from the group consisting of propyl, isobutyl, and -CH_2cyclopropyl.
6. A compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R_6 is isobutyl.
7. A compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R_7 is:



8. A compound according to any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R_7 is:



9. A compound according to any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein r is 1.
10. A compound according to any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein r is 2.
11. A compound according to any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein each R_8 is independently selected from the group consisting of CH_3, OCH_3, CH_2OH, cyclopropyl, fluoro and chloro.
12. A compound according to any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R_8 is CH_2OH.
13. A compound according to any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein r is 0.
14. A compound according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein s is 0.
15. A compound according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein s is 1.
16. A compound according to any of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein u is 2.
17. A compound according to any of claims 1 to 15, or a pharmaceutically acceptable salt

thereof, wherein u is 1.

18. A compound according to any of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein u is 0.

19. A compound according to any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein t is 1 and X is O.

20. A compound according to any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein t is 0.

21. A compound according to any of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein each R_{10} is H.

22. A compound according to any of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein R_{11} is a heterocycloalkyl group selected from oxirane, oxetane, tetrahydrofuran, tetrahydro-2*H*-pyran, pyrrolidine, piperidine, morpholine, morpholin-3-one, and thiomorpholine 1,1-dioxide.

23. A compound according to claim 22, or a pharmaceutically acceptable salt thereof, wherein R_{11} is a heterocycloalkyl selected from tetrahydro-2*H*-pyran and morpholine.

24. A compound according to any of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein R_{11} is cyclohexane.

25. A compound according to any of claims 1 to 22, or a pharmaceutically acceptable salt thereof, wherein R_{11} is unsubstituted.

26. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-[(oxan-4-ylmethoxy)methyl]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[2-(morpholin-4-yl)ethoxy]benzene-1-sulfonamide;

2-[(2,4-dimethylphenyl)(2-methylpropyl)sulfamoyl]-5-(oxan-4-ylmethoxy)benzoic acid;

N-(2,4-dimethylphenyl)-2-methoxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(oxan-4-ylmethyl)amino]methyl}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(cis-3-fluoropiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(piperidin-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(1-methylpyrrolidin-3-yl)methoxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(5-oxomorpholin-2-yl)methoxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(3-methyl-5-oxomorpholin-3-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methoxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-((cis-5-(hydroxymethyl)tetrahydrofuran-2-yl)methoxy)-N-isobutylbenzenesulfonamide;

4-[(3,5-dihydroxycyclohexyl)oxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-(((1S,3R,5S)-3,5-dihydroxycyclohexyl)oxy)-N-(2,4-dimethylphenyl)-N-isobutylbenzenesulfonamide;

4-[2-(3,5-dimethylmorpholin-4-yl)ethoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(oxan-4-ylmethoxy)methyl]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(oxetan-3-ylmethoxy)methyl]benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

3-cyclopropyl-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3,5-difluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-methyl-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-methyl-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-hydroxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

2-chloro-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-fluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-fluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-methoxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxolan-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-hydroxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(morpholin-4-yl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-yloxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-ethoxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-isobutyl-4-(((2R,3R)-2-methylmorpholin-3-yl)methoxy)benzenesulfonamide;

3-cyano-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

2-cyano-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(cis-3-fluoropiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

4-(cyclohexylmethoxy)-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[(2,6-dimethylcyclohexyl)methoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(3-hydroxycyclohexyl)oxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

4-{[(2S)-4,4-difluoropyrrolidin-2-yl]methoxy}-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(6-oxopiperidin-3-yl)oxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-(1,4-dioxan-2-ylmethoxy)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(4-methylcyclohexyl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[1-(morpholin-4-yl)propan-2-yl]oxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(morpholin-2-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(morpholin-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-2-ylmethoxy)benzene-1-sulfonamide;

4-[(6,6-dimethylmorpholin-3-yl)methoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-[2-(morpholin-4-yl)ethoxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{[(2R,3S)-3-hydroxyoxan-2-yl]methoxy}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(4-fluoropiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(2R,3S,4R,5S)-3,4,5-trihydroxyoxan-2-yl]methoxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(1-methylpiperidin-4-yl)oxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{[(cis-3-fluoropiperidin-4-yl)methoxy]methyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2,3-difluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{[1-(2-methoxyethyl)pyrrolidin-3-yl]methoxy}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(1-ethylpyrrolidin-3-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(1-methylpiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(pyrrolidin-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(piperidin-4-yloxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-(piperidin-4-yloxy)benzene-1-sulfonamide;

4-(azetidin-3-ylmethoxy)-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(6-oxopiperidin-3-yl)oxy]methyl}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)-2-(propan-2-yloxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(piperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-(2-(1,1-dioxidothiomorpholino)-1-hydroxyethyl)-N-isobutylbenzenesulfonamide;

N-(2,4-dimethylphenyl)-4-[2-(3-fluoropiperidin-1-yl)-1-hydroxyethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[2-(hydroxymethyl)morpholin-4-yl]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-(4-fluoropiperidin-1-yl)-1-hydroxyethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(piperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[3-(hydroxymethyl)morpholin-4-yl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(3S,4R)-3,4,5-trihydroxyoxolan-2-yl]methoxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(3R,4S,5S)-3,4,5-trihydroxyoxolan-2-yl]methoxy}benzene-1-sulfonamide;

3-chloro-4-[2-(4,4-difluoropiperidin-1-yl)-1-hydroxyethyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-(1-hydroxy-2-{2-oxa-6-azaspiro[3.3]heptan-6-yl}ethyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[trans-(3-hydroxycyclobutyl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-fluoro-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-2-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-3-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-3-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

5-[(2,4-dimethylphenyl)(2-methylpropyl)sulfamoyl]-2-(oxan-4-ylmethoxy)benzoic acid;

2-bromo-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

2-cyclopropyl-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(oxan-4-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(4-methoxypiperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(4-hydroxypiperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

3-cyano-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(4-hydroxypiperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(oxan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(5-oxopyrrolidin-2-yl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-(hydroxymethyl)morpholin-4-yl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3,5-difluoro-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(5-chloro-2-fluorophenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-fluoro-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-2-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-3-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-hydroxy-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

methyl 5-[(2,4-dimethylphenyl)(2-methylpropyl)sulfamoyl]-2-(oxan-4-ylmethoxy)benzoate;

N-(2,4-dimethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(4-ethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(4-ethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2-ethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,2-dihydroxy-3-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,2-dihydroxy-3-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(oxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,3-dihydroxy-2-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,3-dihydroxy-2-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide;

N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide;

(S)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide; and

(R)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide;

27. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide;

N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide;

(S)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide; and

(R)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide.

28. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is (S)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide.

29. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is (R)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide.

30. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide.

31. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

32. A compound as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for use in therapy.

33. A compound as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

34. A compound, or pharmaceutically acceptable salt thereof, for use according to claim 33, wherein the disease is asthma, chronic obstructive pulmonary disease (COPD) , bronchitis, allergic diseases, such as allergic rhinitis and atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatisis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjorgen's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, uveitis, Guillain-Barre syndrome, psoriatic arthritis, Graves' disease or scleritis.
35. A compound, or pharmaceutically acceptable salt thereof, for use according to claim 33, wherein the disease is asthma or chronic obstructive pulmonary disease.
36. A compound, or pharmaceutically acceptable salt thereof, for use according to claim 33, wherein the disease is asthma.
37. A compound, or pharmaceutically acceptable salt thereof, for use according to claim 33, wherein the disease is psoriasis.
38. A method of treatment of an inflammatory, metabolic or autoimmune disease mediated by RORγ comprising administering to a subject in need thereof, a safe and therapeutically effective amount of a compound as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof.
39. A method of treatment according to claim 38, wherein the disease is asthma, chronic obstructive pulmonary disease (COPD) , bronchitis, allergic diseases, such as allergic rhinitis and atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatisis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjorgen's syndrome, optic neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, uveitis, Guillain-Barre syndrome, psoriatic arthritis, Graves' disease or scleritis.
40. A method of treatment according to claim 38, wherein the disease is asthma or chronic obstructive pulmonary disease.
41. A method of treatment according to claim 38, wherein the disease is asthma.
42. A method of treatment according to claim 38, wherein the disease is psoriasis.
43. A method of treatment according to any one of claims 38-42 wherein the subject is a human subject.
44. The use of a compound as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of an inflammatory, metabolic or autoimmune disease mediated by RORγ.
45. The use according to claim 44 wherein the disease is asthma or chronic obstructive

pulmonary disease.

46. The use according to claim 44 wherein the disease is psoriasis.

CLAIMS

1. A compound of formula (Ia), or a pharmaceutically acceptable salt thereof:



(Ia)

wherein R_1 is selected from the group consisting of H, C_{1-3}alkyl, C_{1-3}alkoxy, CF_3, and halo;

R_2, R_3 and R_4 are H;

R_5 is C_{1-3}alkyl;

R_6 is C_{3-5}alkyl or $–CH_2C_{3-4}$cycloalkyl;

R_7 is selected from the group consisting of:



, and



;

each R_8 is independently selected from the group consisting of halo, C_{1-6}alkyl, C_{1-6}alkoxy, C_{3-6}cycloalkyl, CN, OH, C(O)OH, $C(O)OC_{1-3}$alkyl and CH_2OH;

R_9 is the group $–(CHR_{10})_s-(X)_t-(CHR_{10})_u-R_{11}$;

each R_{10} is independently selected from H, CH_3, OH and CH_2OH;

X is CH_2, NH or O;

R_{11} is a heterocycloalkyl or C_{3-6} cycloalkyl group which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of CH_3, OMe, OH, CH_2OH and halo;

r is 0, 1 or 2;

s is 0, 1 or 2;

t is 0 or 1;

u is 0, 1 or 2;

with the proviso that no more than two R_{10} groups represent CH_3, OH or CH_2OH.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R_1 is H.

3. A compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R_6 is isobutyl.
4. A compound according to any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R_7 is:



.

5. A compound according to any of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein r is 1.
6. A compound according to any of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R_8 is CH_2OH.
7. A compound according to any of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein s is 0.
8. A compound according to any of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein u is 1.
9. A compound according to any of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein t is 1 and X is O.
10. A compound according to any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein each R_{10} is H.
11. A compound according to any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R_{11} is a heterocycloalkyl selected from tetrahydro-2*H*-pyran and morpholine.
12. A compound according to any of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R_{11} is unsubstituted.
13. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-[(oxan-4-ylmethoxy)methyl]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[2-(morpholin-4-yl)ethoxy]benzene-1-sulfonamide;

2-[(2,4-dimethylphenyl)(2-methylpropyl)sulfamoyl]-5-(oxan-4-ylmethoxy)benzoic acid;

N-(2,4-dimethylphenyl)-2-methoxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(oxan-4-ylmethyl)amino]methyl}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(cis-3-fluoropiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(piperidin-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(1-methylpyrrolidin-3-yl)methoxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(5-oxomorpholin-2-yl)methoxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(3-methyl-5-oxomorpholin-3-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methoxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-((cis-5-(hydroxymethyl)tetrahydrofuran-2-yl)methoxy)-N-isobutylbenzenesulfonamide;

4-[(3,5-dihydroxycyclohexyl)oxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-(((1S,3R,5S)-3,5-dihydroxycyclohexyl)oxy)-N-(2,4-dimethylphenyl)-N-isobutylbenzenesulfonamide;

4-[2-(3,5-dimethylmorpholin-4-yl)ethoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(oxan-4-ylmethoxy)methyl]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(oxetan-3-ylmethoxy)methyl]benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

3-cyclopropyl-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3,5-difluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-methyl-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-methyl-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-hydroxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

2-chloro-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-fluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-fluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-methoxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxolan-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-hydroxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(morpholin-4-yl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-yloxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2-ethoxy-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-isobutyl-4-(((2R,3R)-2-methylmorpholin-3-yl)methoxy)benzenesulfonamide;

3-cyano-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

2-cyano-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(cis-3-fluoropiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

4-(cyclohexylmethoxy)-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[(2,6-dimethylcyclohexyl)methoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(3-hydroxycyclohexyl)oxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

4-{[(2S)-4,4-difluoropyrrolidin-2-yl]methoxy}-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-[(6-oxopiperidin-3-yl)oxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-(1,4-dioxan-2-ylmethoxy)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(4-methylcyclohexyl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[1-(morpholin-4-yl)propan-2-yl]oxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(morpholin-2-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(morpholin-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-2-ylmethoxy)benzene-1-sulfonamide;

4-[(6,6-dimethylmorpholin-3-yl)methoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-[2-(morpholin-4-yl)ethoxy]benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{[(2R,3S)-3-hydroxyoxan-2-yl]methoxy}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(4-fluoropiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(2R,3S,4R,5S)-3,4,5-trihydroxyoxan-2-yl]methoxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(1-methylpiperidin-4-yl)oxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{[(cis-3-fluoropiperidin-4-yl)methoxy]methyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-2,3-difluoro-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{[1-(2-methoxyethyl)pyrrolidin-3-yl]methoxy}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(1-ethylpyrrolidin-3-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[(1-methylpiperidin-4-yl)methoxy]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(pyrrolidin-3-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(piperidin-4-yloxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-3-(piperidin-4-yloxy)benzene-1-sulfonamide;

4-(azetidin-3-ylmethoxy)-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(6-oxopiperidin-3-yl)oxy]methyl}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)-2-(propan-2-yloxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(piperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-(2-(1,1-dioxidothiomorpholino)-1-hydroxyethyl)-N-isobutylbenzenesulfonamide;

N-(2,4-dimethylphenyl)-4-[2-(3-fluoropiperidin-1-yl)-1-hydroxyethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[2-(hydroxymethyl)morpholin-4-yl]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-(4-fluoropiperidin-1-yl)-1-hydroxyethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(piperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[3-(hydroxymethyl)morpholin-4-yl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(3S,4R)-3,4,5-trihydroxyoxolan-2-yl]methoxy}benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-{[(3R,4S,5S)-3,4,5-trihydroxyoxolan-2-yl]methoxy}benzene-1-sulfonamide;

3-chloro-4-[2-(4,4-difluoropiperidin-1-yl)-1-hydroxyethyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-(1-hydroxy-2-{2-oxa-6-azaspiro[3.3]heptan-6-yl}ethyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[trans-(3-hydroxycyclobutyl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-fluoro-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-2-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-3-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-3-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

5-[(2,4-dimethylphenyl)(2-methylpropyl)sulfamoyl]-2-(oxan-4-ylmethoxy)benzoic acid;

2-bromo-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

2-cyclopropyl-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(oxan-4-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(4-methoxypiperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(4-hydroxypiperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

3-cyano-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

3-chloro-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(4-hydroxypiperidin-1-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(oxan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-N-(2-methylpropyl)-4-(5-oxopyrrolidin-2-yl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[2-(hydroxymethyl)morpholin-4-yl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3,5-difluoro-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(5-chloro-2-fluorophenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-fluoro-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-2-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-3-methyl-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-3-hydroxy-4-[2-hydroxy-1-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

methyl 5-[(2,4-dimethylphenyl)(2-methylpropyl)sulfamoyl]-2-(oxan-4-ylmethoxy)benzoate;

N-(2,4-dimethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzene-1-sulfonamide;

N-(4-ethylphenyl)-4-{1-hydroxy-2-[(3-methyloxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(4-ethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2-ethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,2-dihydroxy-3-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,2-dihydroxy-3-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-{1-hydroxy-2-[(oxetan-3-yl)amino]ethyl}-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,3-dihydroxy-2-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

4-[1,3-dihydroxy-2-(morpholin-4-yl)propyl]-N-(2,4-dimethylphenyl)-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(2,4-dimethylphenyl)-4-[1-hydroxy-2-(morpholin-4-yl)ethyl]-N-(2-methylpropyl)benzene-1-sulfonamide;

N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide;

N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide;

(S)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide; and
(R)-N-(4-ethylphenyl)-4-(1-hydroxy-2-morpholinoethyl)-3-(hydroxymethyl)-N-isobutylbenzenesulfonamide;

14. A compound according to claim 1, or a pharmaceutically salt thereof, which is N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide



.

15. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
16. A pharmaceutical composition comprising a compound as defined in claim 14, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
17. A compound as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for use in therapy.
18. A compound as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.
19. A compound, or pharmaceutically acceptable salt thereof, for use according to claim 18, wherein the disease is asthma, chronic obstructive pulmonary disease (COPD) , bronchitis, allergic diseases, such as allergic rhinitis and atopic dermatitis, cystic fibrosis, lung allograph rejection, multiple sclerosis, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Hashimoto's disease, pancreatisis, autoimmune diabetes, autoimmune ocular disease, ulcerative colitis, Crohn's disease, inflammatory bowel disease (IBS), inflammatory bowel syndrome (IBD), Sjorgen's syndrome, optic

neuritis, type I diabetes, neuromyelitis optica, Myasthenia Gravis, uveitis, Guillain-Barre syndrome, psoriatic arthritis, Graves' disease or scleritis.

20. A compound, or pharmaceutically acceptable salt thereof, for use according to claim 18, wherein the disease is psoriasis.
21. The use of a compound as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of an inflammatory, metabolic or autoimmune disease mediated by RORγ.
22. The use according to claim 21 wherein the disease is psoriasis.